Clinical trials
Multiple myeloma clinical trials
A cancer of plasma cells in the bone marrow that affects the blood and bones. We’re tracking 540 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07073547RecruitingPhase 1
Study of AZD0120 for multiple myeloma patients
This trial tests a new drug, AZD0120, in people with multiple myeloma. It aims to find the right dose and see how safe and effective it is. The study includes both newly diagnosed and early relapsed patients.
Phoenix, ArizonaAges 18 years+ - NCT07032714RecruitingPhase 1
Mezigdomide and talquetamab for relapsed multiple myeloma
This trial tests a combination of two drugs, mezigdomide (a pill) and talquetamab (an injection), for people with multiple myeloma that has come back or not responded to at least three prior treatments. The goal is to see if this combination can help control the disease.
Boston, MassachusettsAges 18 years+ - NCT06997081RecruitingPhase 2
ERd combination for newly diagnosed multiple myeloma
This trial tests a combination of three drugs (elranatamab, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma. The goal is to see if this treatment can lead to a very deep response (no detectable cancer cells) in the bone marrow.
Miami, FloridaAges 18 years+ - NCT06976476RecruitingPhase 2
IgPro20 to prevent infections in multiple myeloma patients on bispecific therapy
This study tests whether a weekly infusion of a blood product called IgPro20 can help prevent infections in people with multiple myeloma who are already being treated with a bispecific antibody. If you qualify, you will receive the study treatment and be monitored for safety and infection rates.
Atlanta, GeorgiaAges 18 years+ - NCT06822972RecruitingPhase 2
Study of Selinexor Plus Bispecific Antibody for Resistant Myeloma
This study tests the drug selinexor in combination with a bispecific antibody for multiple myeloma that has already been treated with at least 4 prior therapies. The goal is to see if the combination is safe and effective for patients whose disease has returned or hasn’t responded to previous treatments.
Durham, North CarolinaAges 18 years+ - NCT06698887Recruiting
Long-term safety study of idecabtagene vicleucel for multiple myeloma in Korea
This study follows up on Korean adults with multiple myeloma who received the CAR T-cell therapy idecabtagene vicleucel (also called Ide-cel) in a previous trial (KarMMa-9) and did not have an optimal response after a stem cell transplant. The goal is to monitor long-term safety.
Hwasun, JeonranamdoAges 18 years+ - NCT06645678RecruitingPhase 1/Phase 2
Mezigdomide and Elranatamab for relapsed or hard-to-treat multiple myeloma
This trial tests two drugs, mezigdomide (a pill) and elranatamab (an injection), in people whose multiple myeloma has come back or not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
SingaporeAges 19 years+ - NCT06508983RecruitingPhase 3
SG301 for multiple myeloma returning after treatment
This trial tests a new drug called SG301 added to standard treatments (pomalidomide and dexamethasone) for people with multiple myeloma that came back or got worse after prior therapy. It may help if you have tried lenalidomide and a proteasome inhibitor but your cancer is still active.
Beijing, Beijing MunicipalityAges 18–75 - NCT06140524RecruitingPhase 2
Study of Linvoseltamab for high-risk MGUS or smoldering myeloma
This trial tests if linvoseltamab can remove abnormal plasma cells that might turn into multiple myeloma. It is for patients with high-risk MGUS (a precancerous condition) or non-high-risk smoldering myeloma who have not yet developed active myeloma.
Baltimore, MarylandAges 18 years+ - NCT05730036RecruitingPhase 3
Linvoseltamab vs standard treatment for relapsed myeloma
This trial compares linvoseltamab against a standard combination (elotuzumab + pomalidomide + dexamethasone) in adults with multiple myeloma that has returned or not responded. It aims to find out whether linvoseltamab works better and is safe for people who have already had some myeloma treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT07609030Recruiting
Brain Training During CAR-T Cell Cancer Treatment
This study tests whether special brain exercises can help protect thinking and memory skills during CAR-T cell therapy—a newer cancer treatment for certain blood cancers. Researchers want to see if training your brain during treatment reduces side effects on memory and mental function.
Columbus, OhioAges 18 years+ - NCT06232096RecruitingPhase 1/Phase 2
Study of MBS314 for relapsed or refractory multiple myeloma
This trial tests a new drug called MBS314 for people whose multiple myeloma has returned or stopped responding to other treatments. The goal is to see if MBS314 can help shrink or control the myeloma.
BeijingAges 18 years+ - NCT07715630RecruitingPhase 1
PICX CAR-T therapy for relapsed or hard-to-treat multiple myeloma
This trial tests a new treatment called PICX CAR-T, a type of immune cell therapy, for multiple myeloma that has come back or not responded well to at least two prior treatments. It aims to see if this therapy can help control the disease.
Kunming, YunnanAges 18 years+ - NCT06574126RecruitingPhase 2
CAR T-cell therapy for high-risk smoldering myeloma
This trial tests a new CAR T-cell therapy (cilta-cel) for people with high-risk smoldering multiple myeloma. It aims to prevent progression to active myeloma.
SalamancaAges 18 years+ - NCT07681596RecruitingPhase 1/Phase 2
Study of a new drug for relapsed or refractory multiple myeloma
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
Duarte, CaliforniaAges 18 years+ - NCT07642362Recruiting
Digital Support to Improve Quality of Life in Multiple Myeloma
This trial tests a digital app designed to help people with multiple myeloma (a blood cancer) manage their quality of life and symptoms. The study wants to see if using this app on a phone or computer can help patients feel better and stay connected to their care.
AthensAges Any age - NCT07579234RecruitingPhase 3
New drug F182112 for hard-to-treat multiple myeloma
This trial tests a new drug called F182112 against standard treatments for multiple myeloma that has stopped responding to previous therapies. The goal is to see if F182112 works better and is safe for patients whose cancer has become resistant to multiple drug classes.
TianjingAges 18 years+ - NCT05665140RecruitingPhase 2/Phase 3
Newly diagnosed myeloma study using blood-marker risk groups
This Phase 2/3 trial tests whether matching treatment choices to a patient’s myeloma risk pattern (using blood and scan results) improves outcomes. It is for people with newly diagnosed, untreated, symptomatic multiple myeloma who may also receive transplant-related treatment.
BerlinAges 18–70 - NCT07541391RecruitingPhase 1
CAR T-cell therapy for relapsed kappa myeloma
This trial tests a new treatment called CAR T-cells (your own immune cells engineered in the lab) designed to fight kappa-restricted multiple myeloma that has come back or stopped responding to standard drugs. The goal is to see if this treatment can help patients whose cancer has progressed despite previous therapies.
Melbourne, VictoriaAges 18 years+ - NCT07369895RecruitingPhase 1
A new cell therapy for relapsed or refractory multiple myeloma
This trial tests a new cell therapy (O&D-001) for multiple myeloma that has returned or not responded to previous treatments. It targets specific markers on myeloma cells (BCMA or GPRC5D) and aims to shrink the cancer.
Guangzhou, GuangdongAges 18–75 - NCT07312188RecruitingPhase 2
F182112 for relapsed or refractory multiple myeloma
This trial tests a new drug, F182112, for people whose multiple myeloma came back or didn't respond to prior treatments that included lenalidomide and a proteasome inhibitor. It may help if your disease has active signs like high protein levels.
TianjinAges 18 years+ - NCT07296627Recruiting
Real-world immunotherapy for newly diagnosed multiple myeloma
This study looks at how well first-line immunotherapy works for people newly diagnosed with multiple myeloma in real-world clinical settings in China. The goal is to understand what treatments are used and how patients respond.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06484829RecruitingPhase 1/Phase 2
New drug combo for relapsed or refractory multiple myeloma
This trial tests a new drug, purinostat mesylate, combined with pomalidomide (a chemotherapy pill) and a low-dose steroid (dexamethasone) for people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to see if this combination can help control the cancer with manageable side effects.
Chengdu, SichuanAges 18–75 - NCT07138209RecruitingPhase 3
Comparing QLS32015 to standard treatments for multiple myeloma
This trial tests a new drug, QLS32015, against two common treatments for multiple myeloma that has come back or not responded to therapy. It may be an option for people who have already tried several treatments.
Tianjin, Tianjin MunicipalityAges 18 years+
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for multiple myeloma?
- Yes. Clin2 currently lists 540 recruiting multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.